小柯机器人

西班牙纳瓦拉大学Ignacio Melero、美国耶鲁大学Kurt A. Schalper等研究人员合作发现，血清白细胞介素8（IL-8）升高与肿瘤内嗜中性粒细胞增多和免疫检查点抑制剂的临床益处降低有关。相关论文于2020年5月11日在线发表于国际学术期刊《自然—医学》。

通过大规模的回顾性分析，研究人员发现基线血清IL-8水平升高与3期临床用纳武单抗和/或伊匹单抗、依维莫司或多西他赛治疗的晚期癌症患者（n=1,344）不良预后相关。研究表明，评估血清IL-8水平对于鉴定不良的肿瘤免疫生物学指标以及作为接受免疫检查点抑制剂患者的独立生物标志物具有重要性。

据了解，血清白细胞介素8（IL-8）水平和中性粒细胞浸润与晚期癌症的预后较差有关。

附：英文原文

Title: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Author: Kurt A. Schalper, Michael Carleton, Ming Zhou, Tian Chen, Ye Feng, Shu-Pang Huang, Alice M. Walsh, Vipul Baxi, Dimple Pandya, Timothy Baradet, Darren Locke, Qiuyan Wu, Timothy P. Reilly, Penny Phillips, Venkata Nagineni, Nicole Gianino, Jianlei Gu, Hongyu Zhao, Jose Luis Perez-Gracia, Miguel F. Sanmamed, Ignacio Melero

Issue&Volume: 2020-05-11

Abstract: Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n=1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.

DOI: 10.1038/s41591-020-0856-x

Source: https://www.nature.com/articles/s41591-020-0856-x

Nature Medicine：《自然—医学》，创刊于1995年。隶属于施普林格·自然出版集团，最新IF：87.241
官方网址：https://www.nature.com/nm/
投稿链接：https://mts-nmed.nature.com/cgi-bin/main.plex